Pain: Do ACE inhibitors exacerbate complex regional pain syndrome?

Nature Reviews Neurology

Volumn 5, Issue 6, 2009, Pages 306-308

  Borsook, David ^a   Sava, Simona ^b  

^a MCLEAN HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTAMIC ACID; NEUROKININ 1 RECEPTOR; POTASSIUM; SUBSTANCE P; SUBSTANCE P ANTAGONIST;

ADRENERGIC SYSTEM; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BACKACHE; COMPLEX REGIONAL PAIN SYNDROME; DRUG MEGADOSE; HUMAN; HYPERALGESIA; MYALGIA; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK ASSESSMENT; SENSITIZATION; SENSORIMOTOR FUNCTION; SMOOTH MUSCLE CONTRACTION; VASODILATATION; CHEMICALLY INDUCED DISORDER; HYPERTENSION; INFLAMMATION; NOTE; PAIN; PATHOPHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMPLEX REGIONAL PAIN SYNDROMES; HUMANS; HYPERTENSION; INFLAMMATION; PAIN;

EID: 68849091854     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2009.73     Document Type: Article

References (10)

1. De Mos, M., Huygen, F. J., Stricker, B. H., Dieleman, J. P. & Sturkenboom, M. C. The association between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain 142, 218-224 (2009).
2. Jänig, W. & Baron, R. Complex regional pain syndrome is a disease of the central nervous system. Clin. Auton. Res. 12, 150-164 (2002).
3. Leeb-Lundberg, L. M., Marceau, F., Müller-esterl, W., Pettibone, D. J. & Zuraw, B. L. International Union of Pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77 (2005).
4. Kopp, U. C., Cicha, M. Z. & Smith, L. A. Angiotensin blocks substance P release from renal sensory nerves by inhibiting PGE2-mediated activation of CAMP. Am. J. Physiol. 285, 472-483 (2003).
5. Parpura, V. et al. Glutamate-mediated astrocyteneuron signalling. Nature 369, 744-747 (1994).
6. Fusayasu, E., Kowa, H., Takeshima, T., Nakaso K. & Nakashima, K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 128, 209-214 (2007).
7. Suzuki, R., Morcuende, S., Webber, M., Hunt, S. P. & Dickenson, A. H. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat. Neurosci. 5, 1319-1326 (2002).
8. Budai, D., Khasabov, S. G., Mantyh, P. W. & Simone, D. A. NK-1 receptors modulate the excitability of ON cells in the rostral ventromedial medulla. J. Neurophysiol. 97, 1388-1395 (2007).
9. McMahon, S. B., Cafferty, W. B. & Marchand, F. Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 192, 444-462 (2005).
10. Hay, J. L. et al. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J. Pain 10, 316-322 (2009).